CYC065 (Fadraciclib) is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9.
CYC065 demonstrates cytotoxicity both in MM cell lines sensitive as well as resistant to conventional chemotherapy with IC50 of 0.06-2 uM.
CYC065 blocks cells in the G1 phase and inhibits cell growth specifically in CCNE1-overexpressing USCs.
CYC065 significantly reduces tumour growth in xenografts derived from CCNE1-amplified USCs.
CYC065 shows synergistic effect in vitro and in vivo combined with Taselisib.
